ID   OV-MZ-15
AC   CVCL_4004
DR   BTO; BTO_0004486
DR   cancercelllines; CVCL_4004
DR   GEO; GSM313678
DR   Progenetix; CVCL_4004
DR   Wikidata; Q54936838
RX   DOI=10.5282/edoc.3898;
RX   PubMed=7510115;
RX   PubMed=11242531;
RX   PubMed=15706405;
RX   PubMed=21559638;
CC   Doubling time: 48 hours (PubMed=7510115).
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7978; Ovarian serous cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   59Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 16
//
RX   DOI=10.5282/edoc.3898;
RA   Euer N.I.;
RT   "Identification of target genes for the therapy and diagnosis of
RT   ovarian carcinoma.";
RL   Thesis PhD (2005); Ludwig Maximilians University of Munich; Munich; Germany.
//
RX   PubMed=7510115; DOI=10.1038/bjc.1994.78; PMCID=PMC1968867;
RA   Mobus V.J., Moll R., Gerharz C.-D., Kieback D.G., Weikel W.,
RA   Hoffmann G., Kreienberg R.;
RT   "Establishment of new ovarian and colon carcinoma cell lines:
RT   differentiation is only possible by cytokeratin analysis.";
RL   Br. J. Cancer 69:422-428(1994).
//
RX   PubMed=11242531; DOI=10.1089/10430340150504019;
RA   Bruning A., Kohler T., Quist S.R., Wang-Gohrke S., Mobus V.J.,
RA   Kreienberg R., Runnebaum I.B.;
RT   "Adenoviral transduction efficiency of ovarian cancer cells can be
RT   limited by loss of integrin beta3 subunit expression and increased by
RT   reconstitution of integrin alphaVbeta3.";
RL   Hum. Gene Ther. 12:391-399(2001).
//
RX   PubMed=15706405; DOI=10.3892/or.13.3.375;
RA   Euer N.I., Kaul S., Deissler H., Mobus V.J., Zeillinger R.,
RA   Weidle U.H.;
RT   "Identification of L1CAM, Jagged2 and neuromedin U as ovarian
RT   cancer-associated antigens.";
RL   Oncol. Rep. 13:375-387(2005).
//
RX   PubMed=21559638; DOI=10.3892/ijo.5.4.753;
RA   Will C., Wilhelm O.G., Hohl S., Mobus V.J., Weidle U.H., Kreienberg R.,
RA   Janicke F., Schmitt M., Graeff H.;
RT   "Expression of urokinase-type plasminogen-activator (uPA) and its
RT   receptor (uPAR) in human ovarian-cancer cells and in-vitro invasion
RT   capacity.";
RL   Int. J. Oncol. 5:753-761(1994).
//